BCIQ Profiles

Company Profile Report

LETTER FROM EDITOR

Aducanumab issue

ADUCANUMAB APPROVAL

Surrogate endpoint

PAYER VIEW

Reimbursement debate

BIOTECH VIEW

Alzheimer's inflection

INVESTOR VIEW

Recalibrating risk

NEXT UP

Lilly, Roche

EDITOR'S COMMENT

Eroding public trust

ACCELERATED APPROVALS

By disease, time

0610 Accelerated Approval indications
BioCentury & Flourish

Regulation

Bringing accelerated approval to the brain

Aducanumab approval marks an expansion of accelerated approval from its origins in HIV and cancer 

Approval of aducanumab marks an expansion of accelerated approval from its origins in HIV and cancer to neurodegenerative disorders.

Jun 11, 2021 | 12:03 AM GMT

FDA’s approval of aducanumab from Biogen for Alzheimer’s disease marks

Read the full 696 word article

How to gain access

Continue reading with a
two-week free trial.